Study of VIP152, Venetoclax, and Prednisone (VVIP) in Relapsed/Refractory Lymphoid Malignancies
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Janssen Research & Development, LLC
Thomas Jefferson University
Thomas Jefferson University
National Cancer Institute (NCI)
Sanofi
Celgene
M.D. Anderson Cancer Center
City of Hope Medical Center
St. Petersburg State Pavlov Medical University
Rhizen Pharmaceuticals SA
medac GmbH
Ain Shams University
Corewell Health West
Bristol-Myers Squibb
Fate Therapeutics
University of Michigan Rogel Cancer Center
Gamida Cell ltd
Radboud University Medical Center
Novartis
Novartis
Gamida Cell ltd
Chinese PLA General Hospital
Mirror Biologics, Inc.
Regimmune Corporation
Maisonneuve-Rosemont Hospital
Mayo Clinic
European Myeloma Network B.V.
National Institutes of Health Clinical Center (CC)
Thomas Jefferson University
Duke University
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
AGC Biologics S.p.A.
University Hospital Tuebingen
University of Michigan Rogel Cancer Center
Dana-Farber Cancer Institute
H. Lee Moffitt Cancer Center and Research Institute
Clavis Pharma
Dana-Farber Cancer Institute
Kiadis Pharma
Stanford University
Assistance Publique - Hôpitaux de Paris
Mashhad University of Medical Sciences
Baylor College of Medicine
Keio University
Accenture
Duke University
M.D. Anderson Cancer Center
Assistance Publique - Hôpitaux de Paris